Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis

Míreanna Comhchosúla

• Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis
  le: Wang, Wenxian, et al.
  Foilsithe: (2018)
• EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
  le: Dong, Kai, et al.
  Foilsithe: (2019)
• A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
  le: Wang, Wenxian, et al.
  Foilsithe: (2016)
• Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy 
in Advanced NSCLC Patients with EGFR Mutations
  le: Minjiang CHEN, et al.
  Foilsithe: (2019-02-01)
• Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study
  le: He ZY, et al.
  Foilsithe: (2019-03-01)